|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 84.61 Million
|
|
Market Size (2030)
|
USD 123.61 Million
|
|
CAGR (2025-2030)
|
6.48%
|
|
Fastest Growing Segment
|
Vaccines
|
|
Largest Market
|
Kanto
|
Market Overview
Japan
Influenza Medications Market was valued at USD 84.61 Million in 2024
and is expected to reach USD 123.61 Million by 2030 with a CAGR of 6.48% during
the forecast period. The Japan Influenza Medications Market is primarily driven
by several key factors. The rising incidence of influenza outbreaks and
seasonal flu contributes significantly to market demand, necessitating
effective antiviral medications and vaccines. Advances in pharmaceutical
research and development have led to the introduction of more effective and
targeted influenza treatments, further boosting market growth. Increased
awareness and proactive healthcare measures, including annual vaccination
campaigns and public health initiatives, drive demand for influenza
medications. Government support for influenza control programs and investments
in healthcare infrastructure also play crucial roles. The market benefits from
continuous innovation in drug formulations and delivery systems, enhancing
treatment efficacy and patient compliance. Demographic factors such as an aging
population, which is more susceptible to severe influenza complications, also
contribute to the growing need for effective influenza medications in Japan.
Key Market Drivers
Rising
Incidence of Influenza Outbreaks
The
increasing frequency of influenza outbreaks in Japan is a major factor driving
the demand for influenza medications. Seasonal flu epidemics, which occur
annually, and occasional pandemics, which may arise less frequently but with
greater impact, create significant public health challenges. Each outbreak
period sees a surge in cases that strain healthcare systems, prompting a
heightened need for effective antiviral treatments to reduce the burden on
hospitals, clinics, and other medical facilities. According to a report,
“Surveillance of seasonal influenza viruses during the COVID‐19 pandemic in Tokyo, Japan,
2018–2023, a single‐center
study”, Japan experienced a notable and extended decline in influenza cases,
with reports for the winter of 2020–2021 showing fewer than 1/1000th of the
usual number of cases, according to the National Institute of Infectious
Diseases. The winter of 2021–2022 saw even lower numbers, marking a new record
low. This two-year period of minimal influenza activity has raised concerns
about potential reduced immunity, especially among the elderly, who are at
higher risk for severe influenza-related complications and mortality.
Influenza
viruses are highly adaptable, with the ability to mutate rapidly and generate
new strains. This constant genetic variability necessitates ongoing
surveillance and the development of updated vaccines and antiviral drugs. For
instance, each flu season may bring new strains that may not be fully covered
by last year's vaccine, requiring pharmaceutical companies and public health
organizations to stay vigilant and responsive. This cyclical nature of
influenza outbreaks drives both public health initiatives and private sector
investments aimed at maintaining an effective arsenal of treatments. Healthcare
providers and governments play crucial roles in managing influenza outbreaks.
Governments often implement vaccination programs and public health campaigns to
increase awareness and vaccination rates. Healthcare providers rely on
effective antiviral medications to treat infected individuals and prevent the
spread of the virus. The demand for these medications spikes during outbreak
periods, emphasizing the need for robust and readily available antiviral
options. This consistent demand fosters a dynamic market environment, where
pharmaceutical companies are encouraged to innovate and develop new treatments
to address emerging strains and improve overall efficacy.
Government
and Public Health Initiatives
Government
and public health initiatives are pivotal drivers of the Japan Influenza
Medications Market. In Japan, both the national government and various public
health organizations play an active role in promoting strategies to manage and
mitigate influenza's impact. These efforts are crucial in controlling the
spread of the virus and reducing the associated healthcare burden on the system.
The Japanese government, through its Ministry of Health, Labour and Welfare
(MHLW), formulates and enforces policies and guidelines that significantly
influence the Japan Influenza Medications Market. The MHLW’s directives include
seasonal vaccination programs, which are critical in preventing influenza
outbreaks and ensuring that the population remains protected. These programs
are supported by public health campaigns that emphasize the importance of
vaccination and early antiviral treatment, thus increasing public awareness and
driving the demand for influenza medications.
Annual
vaccination campaigns spearheaded by the government are aimed at educating the
public about the benefits of receiving the influenza vaccine. By providing
clear communication on the advantages of vaccination—such as reduced severity
of illness and prevention of virus spread—these campaigns help to boost
vaccination rates. The
government’s efforts to make vaccines readily available through subsidization
and public health programs further enhance accessibility, contributing to
increased medication usage. Public health organizations also play a crucial
role in driving the Japan Influenza Medications Market. They collaborate with
healthcare providers to implement best practices in influenza management and
ensure that antiviral medications are used effectively. These organizations
often conduct outreach programs and provide educational resources to healthcare
professionals and the public. By disseminating information on the latest treatment
options and guidelines, they help ensure that patients receive timely and
appropriate care.
Increased
Awareness and Preventive Measures
Rising
awareness about influenza prevention and treatment plays a crucial role in
driving the Japan Influenza Medications Market. This growing awareness stems
from comprehensive public awareness campaigns, educational initiatives, and
extensive media coverage that emphasize the significance of early intervention
and preventive measures. Public awareness campaigns are instrumental in
informing the general population about the risks associated with influenza and
the benefits of vaccination and antiviral treatments. These campaigns are often
spearheaded by government health agencies, non-profit organizations, and healthcare
providers, and they aim to educate the public about the importance of timely
vaccination and effective treatment options. By highlighting the potential
severity of influenza, particularly for high-risk groups such as the elderly,
children, and individuals with chronic health conditions, these initiatives
underscore the need for proactive health measures.
Educational
initiatives are another key driver of increased awareness. Schools, workplaces,
and community centers frequently host informational sessions and workshops that
teach individuals about influenza, its symptoms, and preventive strategies.
These initiatives often include distribution of educational materials such as
brochures, posters, and online resources that provide valuable information on the
importance of flu vaccination and the availability of antiviral medications. By
engaging with various community segments, these programs help to disseminate
critical knowledge and encourage individuals to take preventive actions. Media
coverage also plays a significant role in enhancing public awareness. News
outlets, social media platforms, and health-focused media frequently feature
stories and updates about influenza outbreaks, vaccine availability, and
treatment options. This constant media presence helps keep influenza in the
public eye and reinforces the messages delivered through awareness campaigns
and educational programs. For example, during flu season, news reports might
highlight the benefits of getting vaccinated and the effectiveness of antiviral
medications, thereby motivating individuals to seek out these treatments.
Evolving
Influenza Virus Strains
The
continuous evolution of influenza virus strains is a major driving force behind
the demand for updated medications and vaccines in Japan. Influenza viruses are
highly mutable and exhibit significant genetic variability, which results in
the frequent emergence of new strains. These genetic shifts, including point
mutations and reassortments, can lead to the development of novel virus variants
that may bypass the immunity conferred by previous vaccinations or past
infections. This constant change in the viral landscape creates a pressing need
for new and updated therapeutic and preventive measures. Each flu season, the
influenza virus undergoes genetic changes that can alter its antigenic
properties. This phenomenon, known as antigenic drift, occurs when small
mutations accumulate in the virus’s surface proteins, hemagglutinin (HA) and
neuraminidase (NA). These minor changes can lead to the emergence of new
strains that are sufficiently different from those that circulated in previous
seasons. Consequently, individuals who were previously vaccinated or infected
may not have adequate immunity against these new strains, underscoring the need
for updated vaccines and antiviral drugs.
In
addition to antigenic drift, a more dramatic form of genetic change known as
antigenic shift can occur. Antigenic shift involves the reassortment of genetic
material between different influenza virus strains, potentially creating a
novel influenza subtype with significantly different HA or NA proteins. This
can lead to the emergence of pandemic strains to which the population has
little pre-existing immunity. Historical examples include the H1N1 pandemic of 2009,
which was caused by a new strain resulting from antigenic shift. The potential
for such major shifts necessitates ongoing vigilance and rapid response in
vaccine and drug development to address emergent threats. Pharmaceutical
companies and research institutions play a crucial role in responding to these
evolving viral strains. They continuously monitor influenza virus trends
through global surveillance networks, such as the World Health Organization’s
(WHO) Global Influenza Surveillance and Response System (GISRS). These networks
provide real-time data on circulating strains, enabling scientists to identify
which virus variants are most likely to dominate in the upcoming flu season.
This information is critical for the timely development of vaccines and
antiviral medications that are effective against the currently circulating
strains.
Download Free Sample Report
Key Market Challenges
Resistance
to Antiviral Drugs
One
of the major challenges facing the Japan Influenza Medications Market is the increasing
resistance of influenza viruses to antiviral drugs. Over time, influenza
viruses can develop mutations that render existing antiviral medications less
effective. This resistance can arise due to the overuse or inappropriate use of
antiviral drugs, which can lead to selective pressure on the viruses to evolve
mechanisms that bypass drug action. For instance, resistance to commonly used
antivirals like oseltamivir (Tamiflu) and zanamivir (Relenza) has been
reported, complicating treatment options and necessitating the development of
new and more effective drugs. This resistance not only impacts the
effectiveness of current treatments but also places an additional burden on
healthcare systems and pharmaceutical companies to innovate and develop new antiviral
agents. The challenge is further compounded by the need for ongoing
surveillance of influenza strains to monitor and address resistance patterns,
requiring significant investment in research and development.
High
Costs of Medication and Vaccines
The
high cost of influenza medications and vaccines poses a significant challenge
in the Japan Influenza Medications Market. The development and production of
antiviral drugs and vaccines involve substantial research and development
expenses, which are often passed on to consumers and healthcare providers. The
cost of maintaining a comprehensive vaccination program can strain public
health budgets, especially during years with severe flu seasons or pandemics.
While vaccines and medications are crucial for controlling influenza outbreaks,
their high cost can limit accessibility for some segments of the population,
particularly in economically disadvantaged areas or for those without
sufficient insurance coverage. This financial barrier can lead to lower vaccination
rates and reduced effectiveness of flu management strategies. Addressing this
challenge requires balancing affordability with the need to incentivize
pharmaceutical innovation and ensure widespread access to effective treatments.
Key Market Trends
Growing
Demand for Preventive Vaccines
The
growing demand for preventive vaccines is a major catalyst for the Japan
Influenza Medications Market. Influenza vaccines are essential in controlling
the spread of the virus and mitigating the severity of illness, making them a
cornerstone of public health strategies. The importance of preventive
vaccination has been underscored by public health campaigns that promote annual
flu shots as a key measure to protect individuals and communities from the
influenza virus. In Japan, annual vaccination campaigns are actively supported
by public health authorities, healthcare providers, and government agencies.
These campaigns aim to increase awareness about the benefits of vaccination,
particularly targeting vulnerable populations such as the elderly, children,
and individuals with chronic health conditions. By emphasizing the importance
of timely vaccination before the flu season starts, these campaigns contribute
significantly to higher vaccination rates, which in turn drives demand for
influenza vaccines.
The
development of new and improved vaccines is a direct response to the increasing
demand for effective prevention. Innovations in vaccine technology have led to
the creation of vaccines with broader strain coverage, offering protection
against a wider range of influenza virus variants. This is crucial as influenza
viruses constantly mutate, leading to the emergence of new strains each season.
By providing coverage against multiple strains, these advanced vaccines enhance
their effectiveness and appeal, encouraging more individuals to get vaccinated.
Advancements in vaccine formulations have led to the development of vaccines
with enhanced efficacy. Research and development efforts are focused on
improving the immune response elicited by vaccines, resulting in more effective
protection against influenza. For instance, high-dose or adjuvanted vaccines
have been developed to boost immunity, especially in older adults who may have
a weaker immune response to standard vaccines. These innovations cater to the
increasing demand for vaccines that offer superior protection and help reduce
the overall burden of influenza.
Advancements
in Pharmaceutical Research and Development
Ongoing
advancements in pharmaceutical research and development are crucial in driving
the Japan Influenza Medications Market. Continuous innovations in drug
discovery focus on enhancing the efficacy, safety, and convenience of influenza
medications. Research efforts are dedicated to developing more effective antivirals
and vaccines, with new agents targeting a broader spectrum of influenza strains
and improved resistance profiles. This is essential in combating the rapidly
evolving influenza virus, which can develop resistance to existing treatments.
Advancements in drug delivery systems, such as inhalable or rapid-release
formulations, offer more accessible and user-friendly treatment options.
Investments in research and development ensure that pharmaceutical companies
can offer cutting-edge treatments that address current and emerging strains of
influenza, thereby driving market growth and improving patient care. According
to an article, “Pharmacoeconomic study of anti-influenza virus drugs in Japan
based on a network meta-analysis”, A study was conducted in Japan to evaluate
the most cost-effective neuraminidase inhibitor for treating influenza from a
healthcare payer’s perspective. This analysis revisited a previous study that
had limitations, including the lack of probabilistic sensitivity analysis and
the use of EQ-5D-3L quality of life scores instead of the more current
EQ-5D-5L. The earlier study also used a decision tree model that considered
only three health conditions. In the
updated analysis, new data from a network meta-analysis were incorporated, and
a revised decision tree model was constructed to include seven health
conditions. Costs were assessed based on the 2020 Japanese medical fee index,
including both medical costs and drug prices. Effectiveness was measured using EQ-5D-5L
questionnaires for adult patients with recent influenza virus infections over a
14-day period. Deterministic and probabilistic sensitivity analyses were
conducted to assess uncertainty. The initial analysis confirmed that
oseltamivir was more cost-effective compared to laninamivir, zanamivir, and
peramivir, establishing it as the most cost-effective neuraminidase inhibitor.
The updated examination further validated that oseltamivir continued to
dominate the other neuraminidase inhibitors. Both deterministic and
probabilistic sensitivity analyses consistently supported oseltamivir as the
most cost-effective option among the four drugs.
Segmental Insights
Type Insights
Based on the type, vaccines was the
dominated category among antiviral drugs, antihistamines, and vaccines. Vaccines
play a critical role in the prevention and control of influenza, significantly
influencing the market dynamics. They are pivotal in reducing the incidence of
influenza and mitigating the severity of the disease, particularly during flu
seasons and pandemics.
The dominance of vaccines in the Japan
Influenza Medications Market is driven by several factors. The Japanese
government and public health authorities emphasize preventive measures to
manage influenza outbreaks. Annual vaccination campaigns, supported by
subsidies and public health initiatives, encourage widespread vaccination among
the population. This focus on prevention helps reduce the burden on healthcare
systems by decreasing the number of influenza cases and hospitalizations.
Consequently, vaccines receive substantial support and funding, which fuels
their market dominance. The efficacy of influenza vaccines in preventing the
disease and reducing its spread enhances their appeal. Vaccines are designed to
provide immunity against multiple strains of the influenza virus, including
those anticipated to be prevalent during the flu season. The development of new
and improved vaccines, such as those with broader strain coverage or enhanced
efficacy, further drives their market dominance. Innovations in vaccine
technology, including needle-free delivery systems and combination vaccines,
also contribute to higher vaccination rates and increased market demand.
Route of Administration Insights
Based on Route of Administration, oral
medications dominated over inhaled formulations. Oral
medications, including antiviral drugs and symptomatic treatments, represent a
significant portion of the market due to their widespread use, ease of
administration, and established efficacy. One of the primary reasons oral
medications lead the market is their convenience and broad acceptance among
patients. Oral antiviral drugs, such as neuraminidase inhibitors (e.g.,
oseltamivir) and polymerase inhibitors (e.g., baloxavir), are commonly
prescribed to manage influenza. These drugs are effective in reducing the
severity and duration of influenza symptoms when taken within a specified
period after the onset of symptoms. Oral medications are generally easier to
administer compared to inhaled alternatives, making them more suitable for a
wide range of patients, including those who may have difficulty using inhalers.
The ease of use associated with oral
medications contributes to their dominance. Patients find oral tablets or
capsules more straightforward to take compared to inhalers, which may require
proper technique and coordination to ensure effective delivery of medication to
the respiratory system. This simplicity in administration promotes higher
adherence to prescribed treatments and contributes to the sustained preference
for oral formulations in managing influenza. Oral medications have been
well-established in the market with extensive clinical evidence supporting
their safety and efficacy. Pharmaceutical companies have invested significantly
in developing and refining oral antiviral drugs, leading to a robust portfolio
of options for healthcare providers. The well-documented benefits and
effectiveness of these oral treatments reinforce their position as the preferred
choice for both doctors and patients.
Download Free Sample Report
Regional Insights
In
the Japan Influenza Medications Market, the Kanto region was dominated,
surpassing other regions in terms of market activity and demand for influenza
medications. The Kanto region, which includes major urban centers such as Tokyo
and Yokohama, is the most populous and economically significant region in
Japan. This region's dominance in the Japan Influenza Medications Market can be
attributed to several factors, including its large population, advanced
healthcare infrastructure, and high rate of influenza incidences.
Tokyo,
the capital city of Japan, is a major healthcare hub with a concentration of
medical facilities, research institutions, and pharmaceutical companies. This
concentration leads to a higher demand for influenza medications due to the
dense population and the significant healthcare needs of the residents. The
presence of numerous hospitals, clinics, and specialized centers in Tokyo
ensures that there is a robust infrastructure for diagnosing and treating
influenza, thereby driving up the usage and demand for influenza drugs. The
economic strength of the Kanto region supports extensive healthcare spending
and investments in influenza medications. As one of Japan's leading economic
centers, Tokyo and its surrounding areas benefit from substantial public and
private investments in healthcare, which includes funding for the latest
antiviral drugs, vaccines, and treatment options. This economic capacity
enables the region to maintain high levels of healthcare service quality and
innovation, further boosting the market for influenza medications.
The
high population density in the Kanto region also contributes to its leading
position in the Japan Influenza Medications Market. Dense urban areas are more
prone to influenza outbreaks due to the close proximity of individuals, which
increases the need for effective preventive and therapeutic measures. As a
result, there is a higher demand for influenza vaccines and antiviral medications
to manage and control outbreaks, driving the market growth in this region. Healthcare
infrastructure in Kanto is another critical factor. The region is home to many
top-tier medical institutions and research facilities that contribute to the
development and distribution of new influenza treatments. Hospitals and clinics
in Tokyo and other major cities in the Kanto region are equipped with advanced
diagnostic and treatment technologies, facilitating the prompt and effective
management of influenza cases. This infrastructure supports the widespread
availability and utilization of influenza medications, reinforcing the region's
dominance in the market.
Recent Developments
- In April 2024, Shionogi & Co., Ltd.
announced that its subsidiary, Taiwan Shionogi & Co., Ltd., has received
approval for a supplemental New Drug Application (sNDA) concerning Xofluza®
(baloxavir marboxil). This approval authorizes the use of Xofluza® for treating
and providing postexposure prophylaxis for influenza virus infections in
children aged 5 to under 12 years. While Xofluza® was already available in
Taiwan for adults and children aged 12 and older for the treatment of influenza
A or B and postexposure prophylaxis, this new approval extends its use to
younger children who weigh more than 20 kg, thus offering a new treatment
option for managing influenza in this age group.
- According to a study, “Prescription of
anti-influenza drugs in Japan, 2014–2020: A retrospective study using open data
from the national claims database”, this nationwide retrospective study
examined annual trends in the use of anti-influenza medications in Japan from
2014 to 2020. The estimated number of patients receiving these drugs each year
varied between 6.7 and 13.4 million, with associated costs ranging from JPY
30.1 to 47.1 billion. Patients under the age of 20 represented 46.1% of these
prescriptions. Laninamivir was the most commonly prescribed drug until 2017,
after which it was surpassed by the newly approved baloxavir in 2018. However,
prescriptions for baloxavir saw a significant decline the following year.
- According to a study, “Japanese Surveillance Systems and
Treatment for Influenza”, Japan's influenza management and surveillance
programs are distinguished by several unique features. The national influenza
surveillance system, managed by the National Epidemiological Surveillance for
Infectious Diseases (NESID), includes sentinel outpatient surveillance,
virological monitoring, and reports on hospitalization, mortality, and
influenza-related encephalopathy. Data on student absences and school closures
due to influenza are publicly reported. A private online portal maintained by
volunteer doctors offers real-time information to both clinicians and the
public. For treatment, Japan's national medical insurance covers three classes
of antiviral drugs: M2 inhibitors, neuraminidase inhibitors (NAIs), and a
polymerase inhibitor. Four NAIs—oseltamivir, zanamivir, laninamivir, and
peramivir—are commonly prescribed, with seven to eight million patients treated
annually. NAIs are prescribed to all influenza outpatients, not just severe
cases, and most patients (80–95%) begin treatment within 48 hours of symptom
onset. Laninamivir and peramivir were predominantly used in Japan until
peramivir's FDA approval. Studies indicate that these drugs are as effective as
oseltamivir and zanamivir. Japan's approach has facilitated the introduction of
new antivirals, including polymerase inhibitors and cap-dependent endonuclease
inhibitors, advancing both domestic and global influenza treatment.
Key Market Players
- Novartis Pharma K.K.
- AbbVie GK
- Janssen Pharmaceuticals K.K.
- Asahi Kasei Pharma Corporation
- Sun Pharma Japan Limited
- Kyowa Pharmaceutical Industry Co., Ltd.
- Santen Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Senju Pharmaceutical Co., Ltd.
- Taisho Pharmaceutical Co., Ltd.
|
By Type
|
By Route of Administration
|
By Distribution Channel
|
By Region
|
- Antiviral Drugs
- Antihistamines
- Vaccines
- Others
|
|
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report
Scope:
In
this report, the Japan Influenza Medications Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- Japan
Influenza Medications Market, By Type:
o
Antiviral
Drugs
o
Antihistamines
o
Vaccines
o
Others
- Japan
Influenza Medications Market, By Route of Administration:
o
Oral
o
Inhaled
- Japan
Influenza Medications Market, By Distribution Channel:
o
Hospital
Pharmacies
o
Retail
Pharmacies
o
Online
Pharmacies
- Japan
Influenza Medications Market, By Region:
o
Hokkaido
o
Tohoku
o
Kanto
o
Chubu
o
Kansai
o
Chugoku
o
Shikoku
o
Kyushu
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies present
in the Japan Influenza Medications Market.
Available
Customizations:
Japan
Influenza Medications Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
Japan
Influenza Medications Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]